secwatch.observer — SEC 8-K summary
======================================

Issuer:     EyePoint, Inc. (EYPT)
CIK:        0001314102
Form:       8-K
Filed at:   2022-11-02T23:59:59+00:00
Accession:  0000950170-22-020968
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EyePoint Q3 net product revenue $9.7M (+13% YoY); initiates two Phase 2 trials for EYP-1901; DEXYCU termination
--------------------------------------------------------------------------------

- Q3 net product revenue $9.7M (+13% YoY); net loss $18.4M ($0.49 diluted EPS) vs $16.7M loss prior year.
- Initiated Phase 2 DAVIO 2 (wet AMD) and Phase 2 PAVIA (NPDR) for EYP-1901; topline data expected Q4 2023.
- Final 12-month Phase 1 DAVIO data showed positive safety: 73% reduction in treatment burden, no ocular SAEs.
- DEXYCU commercialization agreement terminated effective Dec 31, 2022 due to CMS pass-through denial.
- Cash $157.3M; expect to fund operations into H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314102/000095017022020968/0000950170-22-020968-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314102/000095017022020968/eypt-20221102.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-020968

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer